KIT and acute myeloid leukemia: KIT aberrations could affect either the tyrosine kinase domain, with substitution of a single amino acid at codon 816 or 822 within exon 17 (higher incidence among CBF AML [14,28]), or the extracellular domain, corresponding to insertions or deletions in exon 8; more rarely, internal tandem duplications in exon 11 could impair the juxtamembrane domain.